ImmunID Technologies : Service Research Contract with Sanofi Pasteur

January 14, 2008 - ImmunID Technologies announced the signature of a Contract Research Service with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and the largest worldwide company entirely devoted to human vaccines.
The innovative technology developed by ImmunID allows the assessment of Human T and B immune repertoires diversity after vaccination...


...About ImmunID
ImmunID Technologies is a young Biotechnology company located in Grenoble, its mission is to develop and commercialise immunomonitoring tests dedicated to pharmaceutical industry and personalized medicine market.
ImmunID offers testing services to monitor the immune repertoire diversity in order to measure the impact of biotherapeutic molecules and to characterize more accurately their efficacy.
ImmunID develops diagnostic products for an early detection of immune related diseases... [PDF] ImmunID Technologies' Press Release -

Sanofi Pasteur , FDA Licenses DAPTACEL® Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series

March 13, 2008 - DAPTACEL vaccine is licensed for the entire immunization series to protect against diphtheria, tetanus, and pertussis -Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) to be administered as a fifth consecutive diphtheria, tetanus, and acellular pertussis (DTaP) vaccine dose for children 4 years through 6 years of age for the prevention of diphtheria, tetanus, and pertussis... [PDF] Sanofi Pasteur's Press Release - version française du PDF -

Sanofi Pasteur and Statens Serum Institut , development and marketing of a new vaccine against Tuberculosis

LYON, France, February 14, 2008 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced that it has signed a collaborative research and license agreement with the Statens Serum Institut of Denmark (SSI) for the development and marketing of a new vaccine against tuberculosis (TB), a disease that causes the death of two million people, worldwide, each year... [PDF] Sanofi Pasteur' Press Release - [PDF] Communiqué de Presse de Sanofi Pasteur-